FI
JNCE

Fosun International’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Fosun International’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-160,000
Closed -$3.58M – 94
2018
Q1 		$3.58M Sell
160,000
-125,960
-44% -$2.8M 0.22% 41
2017
Q4 		$3.65M Hold
285,960
– – 0.32% 30
2017
Q3 		$4.46M Buy
285,960
+193,350
+209% +$2.73M 0.44% 28
2017
Q2 		$1.46M Buy
+92,610
New +$1.98M 0.18% 31

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Fosun International's JNCE Position: Q2 2018 in Review

Fosun International sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2018, closing a stake of 160,000 shares — an estimated $3.58M sold.

Fosun International first reported a position in JNCE in Q2 2017 and held it in 4 quarters. The position peaked at $4.46M in Q3 2017. 83 funds tracked by Wall St. Rank hold JNCE as of Q2 2018.

  • Fosun International reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Fosun International sold 160,000 Jounce Therapeutics, Inc. Common Stock shares in Q2 2018, an estimated $3.58M.
  • Fosun International first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2017 and held it in 4 quarters.
  • Fosun International's Jounce Therapeutics, Inc. Common Stock position peaked at $4.46M in Q3 2017.
  • 83 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2018.

Based on Fosun International's 13F filing for Q2 2018, filed 13 Aug 2018.